Berthold HK, et al. (2006). Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia. JAMA, 295(19): 2262–2269.
Brunzell JD, Failor RA (2006). Diagnosis and treatment of dyslipidemia. In DC Dale, DD Federman, eds., ACP Medicine, section 9, chap. 6. New York: WebMD.
Buckley DI, et al. (2009). C-reactive protein as a risk factor for coronary heart disease: A systematic review and meta-analysis for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 151(7): 483–495.
Centers for Disease Control and Prevention (2009). Prevalence of abnormal lipid levels among youths—United States, 1999–2006. JAMA, 303(10): 930–933.
Genest J, Libby P (2008). Lipoprotein disorders and cardiovascular disease. In P Libby et al., eds., Braunwald's Heart Disease, 8th ed., vol. 1, pp. 1071–1092. Philadelphia: Saunders Elsevier.
Grundy SM, et al. (2001). Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 285(19): 2486–2497.
Kavey RW, et al. (2003). American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation, 107(11): 1562–1566.
Krummel DA (2008). Medical nutrition therapy for cardiovascular disease. In LK Mahan, S Escott-Stump, eds., Krause's Food and Nutrition Therapy, 12th ed., pp. 833–864. St. Louis: Saunders Elsevier.
Maron DJ, et al. (2008). Risk factors for which interventions have proved to lower risk of coronary heart disease section of Preventative strategies for coronary heart disease. In V Fuster et al., eds., Hurst's The Heart, 12th ed., pp. 1208–1217. New York: McGraw-Hill.
McCrindle BW, et al. (2007). Drug therapy of high-risk lipid abnormalities in children and adolescents. A scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation, 115(14): 1948–1967.
Mosca L, et al. (2011). Effectiveness-based guidelines for the prevention of cardiovascular disease in women 2011 update: A guideline from the American Heart Association. Circulation, 123(11): 1243–1262.
National Heart, Lung, and Blood Institute (2005). Your Guide to Lowering Your Cholesterol With TLC (NIH Publication No. 06-5235). Available online: http://www.nhlbi.nih.gov/health/public/heart/chol/chol_tlc.pdf.
Red yeast rice (2009). Medical Letter on Drugs and Therapeutics, 51(1320): 71–72.
Roger VL, et al. (2010). Heart disease and stroke statistics 2011 update: A report from the American Heart Association. Circulation, 123(4): e18–e209.
Sacks FM, et al. (2006). Soy protein, isoflavones, and cardiovascular health: An American Heart Association science advisory for professionals from the Nutrition Committee. Circulation, 113(7): 1034–1044. Also available online: http://circ.ahajournals.org/cgi/content/full/113/7/1034.
U.S. Preventive Services Task Force (2008). Screening for type 2 diabetes mellitus in adults: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine, 148(11): 846–854.
U.S. Preventive Services Task Force (2009). Using Nontraditional Risk Factors in Coronary Heart Disease Risk Assessment. Rockville, MD: Agency for Healthcare Research and Quality. Available online: http://www.uspreventiveservicestaskforce.org/uspstf/uspscoronaryhd.htm.
U.S. Preventive Services Task Force (2009). Aspirin for the Prevention of Cardiovascular Disease. Rockville, MD: Agency for Healthcare Research and Quality. Available online: http://www.ahrq.gov/clinic/uspstf09/aspirincvd/aspcvdrs.htm.